Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MT-101 in CD5+ Relapsed/Refractory T Cell Lymphoma
NCT05138458Phase 2Suspended
- Sponsor
- Myeloid Therapeutics
- Start
- Dec 2021
- Primary completion
- Nov 2024
- Modality
- CAR-T Cells, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of MT-101 in T-cell lymphoma, sponsored by Myeloid Therapeutics. Started Dec 2021; status: suspended.
02
Drugs
MT-101
03
Conditions
T-cell lymphoma
Beyond the preview
Go deeper on NCT05138458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05138458.